<DOC>
	<DOCNO>NCT00005917</DOCNO>
	<brief_summary>Chediak-Higashi syndrome ( CHS ) rare autosomal recessive disorder characterize classical form oculocutaneous albinism , bleed diathesis , recurrent infection due abnormal neutrophil natural killer cell function , eventual progression lymphohistiocytic infiltration know accelerated phase . Death often occur within first decade result infection development accelerate phase ; bone marrow transplantation curative except late occurrence neurological deterioration . The basic defect unknown , although probably involve abnormal fusion traffic intracellular vesicle . Patients classical CHS disease due mutation LYST gene , mildly affected individual report whose genetic defect define . It likely variant CHS abnormality proteins involve pathway responsible vesicle fusion . Since full clinical spectrum CHS variant characterize , underlie defect remain enigmatic , plan evaluate group patient clinically , biochemically , molecularly , perform cell biological study fibroblast , melanocyte , transform lymphoblast . Routine admission 5 day may occur every two year , require change clinical symptomatology .</brief_summary>
	<brief_title>Study Chediak-Higashi Syndrome</brief_title>
	<detailed_description>Chediak-Higashi syndrome ( CHS ) rare autosomal recessive disorder characterize classical form oculocutaneous albinism , bleed diathesis , recurrent infection due abnormal neutrophil natural killer cell function , eventual progression lymphohistiocytic infiltration know accelerated phase . Death often occur within first decade result infection development accelerate phase ; bone marrow transplantation curative except late occurrence neurological deterioration . The basic defect unknown , although probably involve abnormal fusion traffic intracellular vesicle . Patients classical CHS disease due mutation LYST gene , mildly affected individual report whose genetic defect define . It likely variant CHS abnormality proteins involve pathway responsible vesicle fusion . Since full clinical spectrum CHS variant characterize , underlie defect remain enigmatic , plan evaluate group patient clinically , biochemically , molecularly , perform cell biological study fibroblast , melanocyte , transform lymphoblast . Routine admission 5 day may occur every two year , require change clinical symptomatology .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : All patient enter study degree oculocutaneous albinism plus either bleeding diathesis history excessive infection childhood . Objective evidence platelet storage pool deficiency ( e.g. , abnormal secondary aggregation response absent platelet dense body ) lysosomal fusion abnormality ( e.g. , giant cytoplasmic granule leucocyte ) require . EXCLUSION CRITERIA : Patients exclude travel NIH due medical condition . Patients less one month old exclude .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 26, 2017</verification_date>
	<keyword>Albinism</keyword>
	<keyword>Giant Granules</keyword>
	<keyword>Infection</keyword>
	<keyword>Melanosomes</keyword>
	<keyword>Platelet Storage Pool Defect</keyword>
</DOC>